PriceTargets.com logo

Pharvaris - PHVS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $23.00
  • Forecasted Upside: 10.21%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$20.87 As of 09/29/2023 01:00 AM ET
▲ +0.6 (2.96%)

This chart shows the closing price for PHVS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Pharvaris Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PHVS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PHVS

Analyst Price Target is $23.00
▲ +10.21% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Pharvaris in the last 3 months. The average price target is $23.00, with a high forecast of $34.00 and a low forecast of $16.00. The average price target represents a 10.21% upside from the last price of $20.87.

This chart shows the closing price for PHVS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in Pharvaris. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/8/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/7/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/5/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/3/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/3/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/2/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/31/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2023

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/25/2023WedbushInitiated CoverageOutperform$27.00Low
8/15/2023Morgan StanleyUpgradeEqual Weight ➝ Overweight$10.00 ➝ $34.00Low
7/31/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$10.00Low
7/24/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$10.00Low
4/6/2023JMP SecuritiesLower TargetMarket Outperform$23.00 ➝ $20.00Low
2/27/2023JMP SecuritiesReiterated RatingMarket Outperform$23.00Low
2/3/2023SVB LeerinkLower TargetOutperform$20.00 ➝ $18.00Low
1/11/2023JMP SecuritiesBoost TargetMarket Outperform$22.00 ➝ $23.00Low
12/9/2022JMP SecuritiesBoost TargetMarket Outperform$18.00 ➝ $22.00Low
10/5/2022Bryan, Garnier & CoInitiated CoverageBuy$16.00Low
9/14/2022SVB LeerinkLower TargetOutperform ➝ Outperform$25.00 ➝ $20.00Low
9/13/2022JMP SecuritiesLower TargetOutperform ➝ Mkt Outperform$34.00 ➝ $18.00Low
8/23/2022SVB LeerinkLower TargetOutperform$45.00 ➝ $25.00Low
8/23/2022OppenheimerLower TargetOutperform$48.00 ➝ $22.00Low
8/23/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$40.00 ➝ $10.00Low
8/22/2022Bank of AmericaDowngradeNeutral ➝ Underperform$26.00 ➝ $13.00Low
5/25/2022JMP SecuritiesInitiated CoverageOutperform$34.00Low
5/17/2022Morgan StanleyLower TargetOverweight$40.00Low
3/30/2022SVB LeerinkLower TargetOutperform$50.00 ➝ $45.00Medium
4/25/2021SVB LeerinkInitiated CoverageBuyMedium
3/8/2021Morgan StanleyReiterated RatingOverweight$51.00N/A
3/2/2021Morgan StanleyInitiated CoverageOverweight$51.00Low
3/2/2021OppenheimerInitiated CoverageOutperform$48.00Low
3/2/2021SVB LeerinkInitiated CoverageOutperform$50.00Low
3/2/2021Bank of AmericaInitiated CoverageNeutral$41.00Low
(Data available from 9/30/2018 forward)

News Sentiment Rating

0.18 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/4/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2023
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2023
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2023
  • 2 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2023
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2023
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/31/2023
  • 1 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2023

Current Sentiment

  • 1 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Pharvaris logo
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.
Read More

Today's Range

Now: $20.87
Low: $19.86
High: $21.00

50 Day Range

MA: $19.29
Low: $16.26
High: $21.40

52 Week Range

Now: $20.87
Low: $1.77
High: $26.86

Volume

32,619 shs

Average Volume

43,407 shs

Market Capitalization

$664.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Pharvaris?

The following Wall Street sell-side analysts have issued research reports on Pharvaris in the last year: Bryan, Garnier & Co, JMP Securities, Morgan Stanley, SVB Leerink LLC, and Wedbush.
View the latest analyst ratings for PHVS.

What is the current price target for Pharvaris?

5 Wall Street analysts have set twelve-month price targets for Pharvaris in the last year. Their average twelve-month price target is $23.00, suggesting a possible upside of 10.2%. Morgan Stanley has the highest price target set, predicting PHVS will reach $34.00 in the next twelve months. Bryan, Garnier & Co has the lowest price target set, forecasting a price of $16.00 for Pharvaris in the next year.
View the latest price targets for PHVS.

What is the current consensus analyst rating for Pharvaris?

Pharvaris currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PHVS will outperform the market and that investors should add to their positions of Pharvaris.
View the latest ratings for PHVS.

What other companies compete with Pharvaris?

Other companies that are similar to Pharvaris include Aptinyx, GH Research, InterCure, LAVA Therapeutics and NLS Pharmaceutics. Learn More about companies similar to Pharvaris.

How do I contact Pharvaris' investor relations team?

The company's listed phone number is 31-71-203-6410 and its investor relations email address is [email protected]. The official website for Pharvaris is www.pharvaris.com. Learn More about contacing Pharvaris investor relations.